Trial Profile
Efficacy and safety of romiplostim in patients with chronic idiopathic thrombocytopenic purpura
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Apr 2016
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Therapeutic Use
- 25 Apr 2016 New trial record